Bridge the Gap - SYNGAP1 Awareness, Advocacy, Education & Research
BTG - Corporate Alliances
Our Collaborations and partnerships ARE making a POSITIVE impact!
Bridge the Gap's Corporate Alliance is a coalition of rare disease industry stakeholders focused on advancement in neurological disorders, SYNGAP1, and related overlapping disorders.
Bridge the Gap's Corporate Alliance is a committed collaboration between industry, Bridge the Gap and the SYNGAP1 patient community, that is working together to improve and expedite access to effective therapies for SYNGAP1 and overlapping genetic related conditions.
Membership is open to pharmaceutical and biotech companies, industry and academia that want to support patient education, community and capacity building and improved process to accelerate to treatments and research collaborations. The organizations and alliances Bridge the Gap – SYNGAP Education and Research Foundation partners with having a patient focus, community-centered approach and like-minded vision for the future.
Collaborative Goals:
Maintain communication in the current research surrounding neurological disorders, both in development and neurodegenerative medicine surrounding SYNGAP1.
Develop and disseminate consensus policy positions to address identified policy barriers at both the federal and legislative levels.
Promote the creation of new clinical and non-clinical resources to be made available to the undiagnosed community in the neurological space.
Facilitate public engagement between medical and policy experts (and between experts and patients) to discuss issues pertinent to the undiagnosed rare community.
BTG - Corporate Relations Policy
Bridge the Gap – Syngap Education and Research Foundation (“BTG”) will enter into corporate relationships for the sole purpose of providing mission-related benefits to its members and the BTG community.
Bridge the Gap – SYNGAP Education and Research Foundation will not accept any corporate donation or enter into any corporate relationship that would create a conflict of interest or if its appearance, with BTG’s mission, does not align with sound science, or board-approved policies.
All procedures and formal agreements with corporate donors will be designed to prevent any undue influence upon BTG.
Bridge the Gap – Syngap Education and Research Foundation will perform appropriate and adequate due diligence concerning all corporate donors.
We will ensure that the company’s activities, affiliations, and business practices do not compromise our mission.
In all relations with external organizations, Bridge the Gap – Syngap Education and Research Foundation will act in ways that will only enhance the credibility and professional recognition of BTG.
We will ensure that all corporate donations are in alignment with BTG’s mission and are always for the sole benefit of the BTG community.
The Board of Directors has approved the following guidelines and principles regarding corporate support.
BTG's Comprehensive Corporate Relations Policy Includes: General Guiding Principles Regarding BTG and Corporate Relationships/Support
Types of Corporate Support that we accept
Types of Vested Corporate Interactions that we do not endorse or accept
BTG Policy Related to Testimony and Organizational Participation in Food and Drug Administration Hearings and Meetings
BTG Position Statement on Cannabis and Its' Derivatives as a Possible Treatment for Epilepsy
*Click on the button below to read and download a copy of our Corporate Relations Policy
Greenwich Biosciences is the leader in researching cannabinoid medicines for rare epilepsies like Dravet Syndrome, LGS, TSC, and others.is some text inside of a div block.
+1 (240) 347-0302
admin@syngap1foundation.org